Surgalign will sell its U.S. hardware and biomaterials assets and equity interests in non-debtor entities related to international hardware business to Xtant Medical for $5 million, according to a company news release. Surgalign also filed a motion looking to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.
Surgalign’s stock fell 42 percent upon news of its bankruptcy, Seeking Alpha reported June 20. In March, the company announced a 20 percent workforce reduction and sold its Coflex product line to Xtant Medical.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.